Euro
USD
British Pound
NULL
Product Description
Guselkumab is a fully human IgG1 lambda monoclonal antibody that is produced in Chinese Hamster Ovary (CHO) cells. This monoclonal antibody selectively inhibits IL-23 by binding to the p19 subunit of IL-23, blocking its interaction with the receptor (IL-23R), and inhibiting the release of proinflammatory chemokines and cytokines. The antibody was developed by Janssen Biotech and received FDA approval for the treatment of moderate to severe plaque psoriasis. Guselkumab is marketed under the trade name TREMFYA®
Biovision | A2147 | Anti-IL-23? (Guselkumab), Human IgG1 Antibody DataSheet
Antibody Target: IL-23?
Target Alternative Name: CNTO1959, CNTO-1959, TREMFYA, IL23?, IL 23?
Tag Line: Guselkumab is a human monoclonal antibody that selectively targets IL-23 and blocks the interaction with its receptor (IL-23R), thereby inhibiting IL-23 mediated signaling. This monoclonal antibody received FDA approval to treat moderate to severe plaque psoriasis
Category: Biosimilars
Host: Human
Isotype: IgG1, lambda
Species Reactivities: Human
Immunogen Sequence: Guselkumab
Accession #: DB11834
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: 1 mg/ml
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE
